Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Europese Commissie
Onderzoekers en farmabedrijven die nieuwe geneesmiddelen en behandelingen willen testen voor zeldzame kankersoorten.
Ook bekend als HORIZON-MISS-2027-02-CANCER-03, HORIZON-MISS-2027-02, Supporting the implementation of the Cancer Mission
Waar is deze subsidie voor?
Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities; Researchers, physicians, innovators[1], startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation; National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems; Scope: Patients with rare and very rare[2] cancers across EU Member States and Associated Countries often present with advanced disease due to late diagnosis and have access to few treatment options. Hence, these patients typically have a lower 5-year overall survival than those with more common cancers and face challenges with timely access to a small number of appropriate…
Voor wie is het bedoeld?
Onderzoekers en farmabedrijven die nieuwe geneesmiddelen en behandelingen willen testen voor zeldzame kankersoorten.
Waarvoor kunt u subsidie krijgen?
- Zeldzame kanker behandelen
- Biomarker-gestuurde therapie
- Klinische trials zeldzame kanker
- Innovatieve kankerbehandeling
Kom ik in aanmerking?
De eisen uit de regeling. Uw situatie bepaalt of u voldoet; dit is geen beschikking.
Zo vraagt u aan
Zoals beschreven door de verstrekker. Onvolledig? Controleer altijd het officiële loket.
Benodigde documenten
- Clinical study details in dedicated annex using the template provided in the submission system
Aan te leveren gegevens
- Proof of advice from regulators on the design of the clinical trial(s)
- Appropriate mix of stakeholders from various disciplines, regional and national health authorities
- Budget for networking, attendance at meetings, and joint activities for the 'Diagnosis and treatment' cluster
Successful proposals must join the 'Diagnosis and treatment' cluster for the EU Cancer Mission and build on resources from the Knowledge Centre on Cancer (KCC).
Naar het aanvraagloketOpenstellingen en rondes
- Start
- 10 feb 2027
- Sluit
- 21 sep 2027
- Budget
- -
- Verdeling
- Tender
Bronnen en actualiteit
“Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or mul…”
Geen openbare bronnen beschikbaar.
Deze informatie is geautomatiseerd samengesteld uit officiële bronnen en kan onvolledig zijn. Controleer details bij de verstrekker. Elk hard feit toont een citaat uit de brontekst.